Ventricular assist devices in a contemporary pediatric cohort: Morbidity, functional recovery, and survival

Area of Science:

• Pediatric Cardiology
• Mechanical Circulatory Support
• Heart Failure Management

Background:

• Limited donor organ availability necessitates alternative treatments for pediatric heart failure.
• Ventricular Assist Devices (VADs) are primarily used as a bridge to transplantation in children.
• The efficacy of VAD therapy for functional recovery in pediatric patients remains largely unknown.

Purpose of the Study:

• To evaluate the effectiveness of VAD therapy in promoting functional recovery in pediatric heart failure patients.
• To assess morbidity and mortality rates associated with VAD support in children.
• To analyze the relationship between functional status, adverse events, and VAD support duration.

Main Methods:

• Retrospective analysis of 50 pediatric VAD patients from 2004-2013 at a single institution.
• Morbidity and mortality data were collected using the PediMACS criteria.
• Functional status was assessed using the Treatment Intensity Score.

Main Results:

• High survival rates were observed: 98% at 30 days and 83% at 180 days.
• Stroke occurred in 22% of patients, with 16% experiencing persistent neurologic deficit or death.
• Adverse event rates were highest in the initial 7 days of support, decreasing over time.
• Functional status improved with longer VAD support duration.
• Successful bridge to transplantation correlated with fewer adverse events and greater functional improvement.

Conclusions:

• Pediatric VAD therapy demonstrates excellent survival outcomes.
• The risk of serious adverse events diminishes after the first month of support.
• A significant risk of morbidity and mortality persists throughout VAD support.
• Improved functional status correlates with successful transplantation and survival.